CLARITEV CORP (CTEV) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CTEV - US62548M2098 - Common Stock
30.47 USD
-1.95 (-6.01%)
30.47 USD
0 (0%)
We assign a fundamental rating of 2 out of 10 to CTEV. CTEV was compared to 35 industry peers in the Health Care Technology industry. Both the profitability and financial health of CTEV have multiple concerns. CTEV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year CTEV has reported negative net income.
- CTEV had a positive operating cash flow in the past year.
- In the past 5 years CTEV reported 4 times negative net income.
- CTEV had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- CTEV has a better Return On Assets (-6.85%) than 65.71% of its industry peers.
- The Return On Invested Capital of CTEV (0.82%) is better than 62.86% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for CTEV is below the industry average of 6.61%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.85% | ||
| ROE | N/A | ||
| ROIC | 0.82% |
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
1.3 Margins
- Looking at the Operating Margin, with a value of 5.21%, CTEV is in the better half of the industry, outperforming 68.57% of the companies in the same industry.
- In the last couple of years the Operating Margin of CTEV has declined.
- CTEV's Gross Margin of 74.72% is fine compared to the rest of the industry. CTEV outperforms 74.29% of its industry peers.
- CTEV's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.21% | ||
| PM (TTM) | N/A | ||
| GM | 74.72% |
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
2. Health
2.1 Basic Checks
- CTEV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- CTEV has about the same amout of shares outstanding than it did 1 year ago.
- The number of shares outstanding for CTEV has been reduced compared to 5 years ago.
- CTEV has a worse debt/assets ratio than last year.
2.2 Solvency
- CTEV has an Altman-Z score of -0.36. This is a bad value and indicates that CTEV is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -0.36, CTEV is in line with its industry, outperforming 45.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.36 |
ROIC/WACC0.12
WACC6.58%
2.3 Liquidity
- A Current Ratio of 1.21 indicates that CTEV should not have too much problems paying its short term obligations.
- CTEV's Current ratio of 1.21 is on the low side compared to the rest of the industry. CTEV is outperformed by 77.14% of its industry peers.
- CTEV has a Quick Ratio of 1.21. This is a normal value and indicates that CTEV is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.21, CTEV is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 |
3. Growth
3.1 Past
- CTEV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.52%, which is quite impressive.
- Looking at the last year, CTEV shows a small growth in Revenue. The Revenue has grown by 0.89% in the last year.
- Measured over the past years, CTEV shows a decrease in Revenue. The Revenue has been decreasing by -1.09% on average per year.
EPS 1Y (TTM)67.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.56%
Revenue 1Y (TTM)0.89%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%6.71%
3.2 Future
- Based on estimates for the next years, CTEV will show a very strong growth in Earnings Per Share. The EPS will grow by 22.18% on average per year.
- Based on estimates for the next years, CTEV will show a small growth in Revenue. The Revenue will grow by 3.86% on average per year.
EPS Next Y76.22%
EPS Next 2Y34.19%
EPS Next 3Y22.18%
EPS Next 5YN/A
Revenue Next Year2.91%
Revenue Next 2Y3.39%
Revenue Next 3Y3.86%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CTEV. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTEV. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- CTEV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CTEV is cheaper than 82.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10.42 |
4.3 Compensation for Growth
- CTEV's earnings are expected to grow with 22.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.19%
EPS Next 3Y22.18%
5. Dividend
5.1 Amount
- No dividends for CTEV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
30.47
-1.95 (-6.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-07 2025-11-07/bmo
Earnings (Next)02-23 2026-02-23/bmo
Inst Owners48.15%
Inst Owner ChangeN/A
Ins Owners6.93%
Ins Owner Change0.62%
Market Cap503.67M
Revenue(TTM)951.00M
Net Income(TTM)-341.68M
Analysts84.44
Price Target90.1 (195.7%)
Short Float %8.59%
Short Ratio3.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.42%
Min EPS beat(2)-15.41%
Max EPS beat(2)2.57%
EPS beat(4)2
Avg EPS beat(4)-5.44%
Min EPS beat(4)-23.58%
Max EPS beat(4)14.65%
EPS beat(8)4
Avg EPS beat(8)-188.45%
EPS beat(12)6
Avg EPS beat(12)-288.48%
EPS beat(16)7
Avg EPS beat(16)-215.53%
Revenue beat(2)2
Avg Revenue beat(2)2.38%
Min Revenue beat(2)2.26%
Max Revenue beat(2)2.51%
Revenue beat(4)3
Avg Revenue beat(4)0.94%
Min Revenue beat(4)-2.88%
Max Revenue beat(4)2.51%
Revenue beat(8)3
Avg Revenue beat(8)-1.92%
Revenue beat(12)5
Avg Revenue beat(12)-1.32%
Revenue beat(16)7
Avg Revenue beat(16)-1.84%
PT rev (1m)0%
PT rev (3m)25.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.21%
EPS NY rev (1m)-2.82%
EPS NY rev (3m)-3.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.41%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)1.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.53 | ||
| P/FCF | N/A | ||
| P/OCF | 28.53 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.42 |
EPS(TTM)-20.48
EYN/A
EPS(NY)-13.87
Fwd EYN/A
FCF(TTM)-6.79
FCFYN/A
OCF(TTM)1.07
OCFY3.51%
SpS57.53
BVpS-6.16
TBVpS-270.62
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.85% | ||
| ROE | N/A | ||
| ROCE | 1.04% | ||
| ROIC | 0.82% | ||
| ROICexc | 0.83% | ||
| ROICexgc | 10.68% | ||
| OM | 5.21% | ||
| PM (TTM) | N/A | ||
| GM | 74.72% | ||
| FCFM | N/A |
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
ROICexc(3y)2.48%
ROICexc(5y)N/A
ROICexgc(3y)66.67%
ROICexgc(5y)N/A
ROCE(3y)3.05%
ROCE(5y)N/A
ROICexgc growth 3Y-40.96%
ROICexgc growth 5Y-27.14%
ROICexc growth 3Y-26.84%
ROICexc growth 5Y-14.89%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
F-Score6
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 9.38 | ||
| Cap/Depr | 29.31% | ||
| Cap/Sales | 13.65% | ||
| Interest Coverage | 0.14 | ||
| Cash Conversion | 3.59% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.21 | ||
| Quick Ratio | 1.21 | ||
| Altman-Z | -0.36 |
F-Score6
WACC6.58%
ROIC/WACC0.12
Cap/Depr(3y)25.06%
Cap/Depr(5y)22.79%
Cap/Sales(3y)10.77%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.56%
EPS Next Y76.22%
EPS Next 2Y34.19%
EPS Next 3Y22.18%
EPS Next 5YN/A
Revenue 1Y (TTM)0.89%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%6.71%
Revenue Next Year2.91%
Revenue Next 2Y3.39%
Revenue Next 3Y3.86%
Revenue Next 5YN/A
EBIT growth 1Y-61.12%
EBIT growth 3Y-37.5%
EBIT growth 5Y-23.25%
EBIT Next Year145.66%
EBIT Next 3Y35.58%
EBIT Next 5YN/A
FCF growth 1Y-263.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.72%
OCF growth 3Y-35.69%
OCF growth 5Y-17.66%
CLARITEV CORP / CTEV FAQ
Can you provide the ChartMill fundamental rating for CLARITEV CORP?
ChartMill assigns a fundamental rating of 2 / 10 to CTEV.
What is the valuation status of CLARITEV CORP (CTEV) stock?
ChartMill assigns a valuation rating of 1 / 10 to CLARITEV CORP (CTEV). This can be considered as Overvalued.
What is the profitability of CTEV stock?
CLARITEV CORP (CTEV) has a profitability rating of 3 / 10.
What is the earnings growth outlook for CLARITEV CORP?
The Earnings per Share (EPS) of CLARITEV CORP (CTEV) is expected to grow by 76.22% in the next year.